The Ministry of health told about clinical trials of drugs COVID-19
Clinical studies of the Russian drug from COVID-19 "of Favipiravir" financial under the name "Replevin" is expected to finish in four to eight weeks, said chief urologist of Ministry of health of Russian Federation, academician Dmitry Pushkar responsible for the implementation of the Protocol studies of the drug in Russia.
earlier in the press service of the Ministry of health of Russia said Last news that the deadline to market the drug from COVID-19 " Favipiravir ", which is currently undergoing Clinical validation, will be reduced.
"We hope that Clinical testing will be completed for 4 to eight weeks, after which it will be transferred the documents for registration," said he Last news .
He said that Clinical trials of the drug will be conducted in several hundred patients, not only in the capital of Russia, but in St. Petersburg, in Mordovia, where the drug is produced.
in the first phase, the drug will be used only For patients of moderate severity. For severe patients, those placed on a ventilator, He as long as use does not become, said Pushkar. Later studies will be undertaken To use and difficult patients, He explained.
"Exactly that a drug will occur Earlier vaccine, but it is necessary to work in the other direction," - drew the attention of Pushkar.
Current information on the situation of COVID-19 in Russia and the world presented on the portal stopmanager. Of the Russian Federation.
<span style="color:darkgray
|
